BEST vCLI Registry

Critical Limb Ischemia Clinical Trial

— BEST  

Official title:

BEST Critical Limb Ischemia (vCLI) Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04191746
• Other study ID #: Pro00102178
• Secondary ID: 1R01HL141213-01
• Status: Completed
• Start date: December 9, 2019
• Est. completion date: September 25, 2023

Study information

• Verified date: April 2024
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

For subjects with critical limb ischemia, identify patient, physician/hospital, and geographic factors associated with variations in treatment strategies; compare treatments and outcomes, including quality of life, cost and cost effectiveness, at 6, 12 months.

Description:

The study will be a prospective multicenter registry evaluating the real world therapeutic strategies, clinical outcomes, and costs associated with patients presenting with critical limb ischemia.

Population: Patients over age 18 presenting with critical limb ischemia After initial enrollment at 40 study sites throughout the US. participants will complete follow-up 6 months and 12 months via call center telephone calls.

The study plan calls for enrollment of approximately 1,200 participants throughout the US that will then have 12 month followup that includes collection of medications, hospitalizations for collection of events.Additionally, the BEST-CLI trial will be gathering quality of life data and cost data using similar instruments, thus providing an opportunity for comparison between cost and quality of life analyses in a clinical trial versus in a real-world registry and collection of Quality of Life using validated instruments: EQ-5D, VASQOL, SF-12.and bill review to determine economic impact of disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1009
• Est. completion date: September 25, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female

• age 18 years or older

• Infrainguinal peripheral artery disease (occlusive disease of the arteries below the inguinal ligament)

• Critical limb ischemia, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain consistent with Rutherford categories 4-6

• Documented consideration for enrollment in the BEST-CLI Trial with documented failure to meet inclusion / exclusion criteria. Phase ll After BEST CLI official enrollment ends, this inclusion criteria will be removed.

• Willingness to comply with vCLI protocol, attend follow-up appointments, complete all study assessments, and provide written informed consent.

Exclusion Criteria:

• Presence of a popliteal aneurysm (> 2 cm) in the index limb

• Life expectancy of less than 2 years due to reasons other than peripheral artery disease

• Active vasculitis, Buerger's disease, or acute limb-threatening ischemia

• Current chemotherapy or radiation therapy

• Pregnancy or lactation

• Administration of an investigational drug for peripheral artery disease within 30 days of randomization

• Participation in a clinical trial (except observational studies) within the previous 30 days

• Prior enrollment or randomization into the BEST-CLI trial

Related Conditions & MeSH terms

• Chronic Limb-Threatening Ischemia
• Critical Limb Ischemia
• Ischemia

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)	Number of participants in the registry with major limb events as reported by participants and confirmed by medical records	6 months
Primary	Percentage of participants with major adverse limb events (MALE) as measured by patient reports (verified by medical records)	Number of participants in the registry with major limb events as reported by participants and confirmed by medical records	12 months
Secondary	Number of participants that died within 30 days of index procedure	Collect composite of MALE or perioperative death within 30 days of index procedure using patient/proxy information qualified by medical records.	30 days
Secondary	Number of participants with amputation free survival as measured by patient report/verified by medical record review	Interviews completed at 6 months with participants that note no hospitalization for amputation and verified by medical records	6 months
Secondary	Number of participants with amputation free survival as measured by patient report/verified by medical record review	Interviews completed at 12 months with participants that note no hospitalization for amputation and verified by medical records	12 months
Secondary	Number of participants that did not have secondary interventions in index leg as measured by patient report/verified by medical record review	At 6 month visit, the number of participants that did not report additional procedures such as surgery or angiography.in the affected leg	6 months
Secondary	Number of participants that did not have secondary interventions in index leg as measured by patient report/verified by medical record review	At 12 month visit, the number of participants that did not report additional procedures such as surgery or angiography.in the affected leg	12 months
Secondary	Number of interventions per limb as measured by patient report/verified by medical record review	Interventions consist of need to be hospitalized for a form of revascularization	6 months
Secondary	Number of interventions per limb as measured by patient report/verified by medical record review	Interventions consist of need to be hospitalized for a form of revascularization	12 months
Secondary	Number of participants that did not have limb revascularization failure as measured by patient report/verified by medical record review	Limb revascularization failure is loss of circulation to the limb that has procedural revascularization previously performed that is non functioning	6 months
Secondary	Number of participants that did not have limb revascularization failure as measured by patient report/verified by medical record review	Limb revascularization failure is loss of circulation to the limb that has procedural revascularization previously performed that is non functioning	12 months
Secondary	Number of participants who did not have a myocardial infarction as measured by patient report/verified by medical record review	Number of participants that answered no to the question "Was your hospitalization for a Heart Attack(MI) at 6 months verified by medical record.	6 months
Secondary	Number of participants who did not have a myocardial infarction as measured by patient report/verified by medical record review	Number of participants that answered no to the question "Was your hospitalization for a Heart Attack(MI) at 12 months verified by medical record.	12 months
Secondary	Number of participants who did not have a stroke while in the registry as measured by patient report/verified by medical record review	Stroke is inclusive of a cerebral vascular including a ischemic, hemorrhagic or a TIA event.	6 months
Secondary	Number of participants who did not have a stroke while in the registry as measured by patient report/verified by medical record review	Stroke is inclusive of a cerebral vascular including a ischemic, hemorhagic or a TIA event.	12 months
Secondary	Number of participants that did not have a periprocedural (30 day) major adverse cardiac events as measured by patient report/verified by medical record review	Events that occur during a revascularization procedure including cardiovascular events such as Myocardial Infarction and stoke.	6 months
Secondary	Quality of life as measure by the validated QOL tool called the EuroQol that will be administered throughout the study	The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression. I also includes a 0-100 scale regarding participants assessment of health.	Baseline
Secondary	Quality of life as measure by the validated QOL tool called the EuroQol that will be administered throughout the study	The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression. I also includes a 0-100 scale regarding participants assessment of health.	6 month
Secondary	Quality of life as measure by the validated QOL tool (EuroQol) that will be administered throughout the study	The EuroQol is a 6 question validated instrument that asks questions regarding mobility, self care, usual activities, pain/discomfort and anxiety and depression with a range of 5 answers. I also includes a 0-100 scale regarding participants assessment of health.	12 month
Secondary	Quality of life as measured by the the SF-12 instrument that will be administered throughout the study	The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view	Baseline
Secondary	Quality of life as measured by the the SF-12 instrument that will be administered throughout the study	The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view	6 months
Secondary	Quality of life as measured by the the SF-12 instrument that will be administered throughout the study	The SF-12 Health Survey is a shorter version of the SF-36 Health Survey that uses 12 questions to measure functional health and well-being from the patient's point of view	12 months